ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1989

Netrin-1 and Its Receptor Unc5B Mediates Tenofovir Induced Bone Loss and Dipyridamole, an Agent That Blocks Adenosine Transporter, Is Able to Modulate the Signal

Aranzazu Mediero1, Patricia Llamas-Granda 2, Bruce Cronstein 3, Raquel Largo 4 and Gabriel Herrero-Beaumont 4, 1IIS-FUNDACION JIMENEZ DIAZ, Madrid, Spain, 2IIS-FUNDACION JIMENEX DIAZ, Madrid, Spain, 3Department of Medicine, Division of Rheumatology NYUSoM, NYC, 4IIS-Fundación Jiménez Díaz, Madrid, Madrid, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: adenosine receptors and Netrin-1, bone remodeling, Cell Signaling, osteoclasts

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Osteoarthritis & Joint Biology – Basic Science Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteopenia and fragility fractures have been associated with HIV infection. Tenofovir, a common antiviral in HIV treatment, also leads to increases in bone catabolism markers and decreased bone mineral density (BMD) in children and young adults. In murine models and human cell lines, tenofovir inhibits ATP release and decreases extracellular adenosine levels. We have recently reported that Netrin-1 is an autocrine and paracrine regulator of osteoclast differentiation with unique role for Netrin-1 in osteoclast biology and inflammation. We have also described that blosckade of adenoine uotaken with dipyridamole, prevent bone loss caused by tenofovir in mice. We hypothesized that Netrin1 might be involved in bone resorption induced by tenofovir, and if we increase adenosine levels, we could revert the deleterious effect of tenofovir.

Methods: Male C57Bl/6 mice were treated as follows: IP injection of saline (control), tenofovir 75mg/Kg/day, dipyridamole 25mg/Kg/day, combination tenofovir/dipyridamole (n=10, 4 weeks) and after sacrifice, long bones were prepared for histology. Primary murine M-CSF/RANKL-induced were challenge with Tenofovir 1mM alone or in combination with Dipyridamole 1mM, and expression of Netrin-1 and its receptors Unc5B and DCC were study by Western Blot.

Results: Mice treated with tenofovir showed an increased expression of Netrin-1 and its receptor Unc5b when compare to control mice, and treatment with Dipyridamole partially reverting the expression of these molecules. In vitro, tenofovir tenofovir increases Netrin1 expression (44±4% increased vs. basal, p< 0.05) and secretion (16±5% increased vs. basal, p=ns) and Unc5b expression (74±18% increased vs. basal, p< 0.05) 24 hours after stimulation, and pre-treatment with dipyridamole reverted the effect. No changes in DCC expression were observed.

Conclusion: These results suggest that Netrin-1/Unc5b might be involved in bone resorption mediated by tenofovir, and treatment with agents that increase local adenosine concentrations, like Dipyridamole, might prevent this bone loss.


Disclosure: A. Mediero, None; P. Llamas-Granda, None; B. Cronstein, Abbott, 4, Amgen, AstraZeneca, 5, Baxter, 4, Bristol-Myers Squibb, 4, CanFite Biopharma, 4, Eli Lilly & Co, 5, Gilead, 4, Horizon Pharmaceuticals, 5, NIH, Arthritis Foundation, Kairos, 2, Novartis, 4, Patent Pending for the use of adenosine receptor agonists for the treatment of OA, Patents pending for use of adenosine receptor agonist and antagonist for treatment of bone, liver diseases and wound healing, Regenosine, 4, Regenosine, Inc, 4, 6; R. Largo, None; G. Herrero-Beaumont, None.

To cite this abstract in AMA style:

Mediero A, Llamas-Granda P, Cronstein B, Largo R, Herrero-Beaumont G. Netrin-1 and Its Receptor Unc5B Mediates Tenofovir Induced Bone Loss and Dipyridamole, an Agent That Blocks Adenosine Transporter, Is Able to Modulate the Signal [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/netrin-1-and-its-receptor-unc5b-mediates-tenofovir-induced-bone-loss-and-dipyridamole-an-agent-that-blocks-adenosine-transporter-is-able-to-modulate-the-signal/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/netrin-1-and-its-receptor-unc5b-mediates-tenofovir-induced-bone-loss-and-dipyridamole-an-agent-that-blocks-adenosine-transporter-is-able-to-modulate-the-signal/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology